Argenica Therapeutics (ASX:AGN) Buyback Yield %: -0.02 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
30 GF Score
Price A$0.15
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Buyback Yield %?

Argenica Therapeutics ASX:AGN +3.57% 30 Buyback Yield % is -0.02 as of Jul. 14, 2026. GuruFocus rates ASX:AGN with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, Argenica Therapeutics ranks better than 84.77% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Argenica Therapeutics's current buyback yield was -0.02%.

Argenica Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Buyback Yield % Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
-53.63 -13.73 -10.10 -12.02 -0.36

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -7.83 -12.02 -14.56 -0.36 -0.01

ASX:AGN vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Argenica Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argenica Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's Buyback Yield % falls into.


ASX:AGN
30GF Score
Argenica Therapeutics Ltd ASX:AGN
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Argenica Therapeutics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.347) / 97.6182
=-0.36%

Argenica Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0.019 + -0.016) / 37.894815
=-0.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -0.02 mean?
Argenica Therapeutics (ASX:AGN) has a Buyback Yield % of -0.02 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Argenica Therapeutics and its competitors. According to the industry distribution chart, Argenica Therapeutics ranks #113 out of 742 companies in the Biotechnology industry, placing it in the top 15.2%.
Is Argenica Therapeutics' Buyback Yield % too high?
Argenica Therapeutics' current Buyback Yield % is -0.02. Based on the distribution chart, Argenica Therapeutics ranks #113 out of 742 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Argenica Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Argenica Therapeutics ranks #113 out of 742 companies for Buyback Yield %. This places Argenica Therapeutics in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current Buyback Yield % is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Buyback Yield % of -0.02. The current Buyback Yield % is -0.02. Argenica Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Buyback Yield % is -0.02 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
30GF Score

Get the complete analysis for ASX:AGN

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price